RXRX
Recursion Pharmaceuticals-A
NASDAQ · Biotechnology
$3.98
+0.42 (+11.80%)
Performance
1D
—
1W
-4.78%
1M
-17.26%
3M
-15.50%
6M
-30.18%
1Y
-47.97%
YTD
-5.24%
Open$3.74
Previous Close$3.56
Day High$4.02
Day Low$3.69
52W High$12.36
52W Low$3.54
Volume26.17M
Avg Volume22.94M
Market Cap2.07B
P/E Ratio—
EPS$-1.81
SectorBiotechnology
Volume Analysis
1.14x average volume
Technical Indicators
SMA 50
$4.46
Below
SMA 200
$4.97
Below
RSI (14)
37.1
Neutral
Trend
Death Cross
Bearish
Analyst Ratings
Buy
14 analysts
Price Target
+626.1% upside
Current
$3.98
$3.98
Target
$28.90
$28.90
$21.05
$28.90 avg
$39.88
Key Financials
| FY 2026 | FY 2025 | FY 2025 | |
|---|---|---|---|
| Revenue | 111.69M | 62.24M | 351.21M |
| Net Income | -880,041,098 | -441,344,582 | -18,064,955 |
| Profit Margin | -788.0% | -748.6% | -5.1% |
| EBITDA | -873,431,291 | -462,364,719 | -22,133,294 |
| Free Cash Flow | — | — | -14,520,850 |
| Rev Growth | +79.5% | +79.5% | -2.2% |
| Debt/Equity | 0.03 | 0.03 | 0.45 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |